Agf Investments Inc. Neurocrine Biosciences Inc Transaction History

Agf Investments Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $370,070 - $504,584	-4,226 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$86.91 - $108.33 $123,064 - $153,395	-1,416 Reduced 25.1%	4,226 $405,000
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $300,115 - $421,803	3,121 Added 123.8%	5,642 $543,000
Q2 2020 Aug 11, 2020	SELL	$85.09 - $130.36 $45,693 - $70,003	-537 Reduced 17.56%	2,521 $308,000
Q1 2020 May 08, 2020	BUY	$75.11 - $113.76 $229,686 - $347,878	3,058 New	3,058 $265,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Agf Investments Inc., based on Form 13F filings with the SEC.

Stay updated on Agf Investments Inc. with notifications on news.